Page 32 - Read Online
P. 32

Page 14 of 18                 Padoan et al. Vessel Plus 2021;5:41  https://dx.doi.org/10.20517/2574-1209.2021.41

               crucial for readily arriving at the proper diagnosis, which allows the timely initiation of appropriate therapy.
               Therefore, AAV patients must be followed up regularly and frequently, in order to detect early relapses and
               reduce damage accrual of the affected areas.


               DECLARATIONS
               Authors’ contributions
               Conceptualization: Padoan R, Campaniello D, Felicetti M, Cazzador D, Schiavon F
               Investigation: Padoan R, Schiavon F
               Writing review: Padoan R, Campaniello D, Felicetti M, Cazzador D, Schiavon F
               Editing: Padoan R, Cazzador D, Schiavon F
               Drafting and revising figures: Padoan R, Cazzador D
               Supervision of ENT surgery topics: Cazzador D, Schiavon F

               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of
                    antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
                    Arthritis Rheum 2012;64:3452-62.  DOI  PubMed  PMC
               2.       Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis.
                    Summary. Arthritis Rheum 1990;33:1135-6.  DOI  PubMed
               3.       Kallenberg CGM. Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Curr
                    Opin Rheumatol 2016;28:8-14.  DOI  PubMed
               4.       Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-
                    23.  DOI  PubMed  PMC
               5.       Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.
                    Neurology 2020;94:E1726-37.  DOI  PubMed
               6.       Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis:
                    Does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934-9.  DOI  PubMed
               7.       Felicetti M, Cazzador D, Padoan R, et al. Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and
                    how it determines disease severity and long-term outcomes. Clin Rheumatol 2018;37:1075-83.  DOI  PubMed
               8.       Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel
                    vasculitis. Ann Rheum Dis 2009;68:310-7.  DOI  PubMed
               9.       Yates M, Watts R. ANCA-associated vasculitis. Clin Med 2017;17:60-4.  DOI  PubMed  PMC
               10.       Nishi R, Koike H, Ohyama K, et al. Association between IL-5 levels and the clinicopathologic features of eosinophilic
                    granulomatosis with polyangiitis. Neurology 2021;96:226-9.  DOI  PubMed
               11.       Bligny D, Mahr A, Toumelin P Le, et al. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93
                    patients. Arthritis Rheum 2004;51:83-91.  DOI  PubMed
   27   28   29   30   31   32   33   34   35   36   37